There are many challenges in selecting biologic therapies for patients with inflammatory bowel disease. touchIMMUNOLOGY were delighted to speak with Dr. Christopher V. Almario (Cedars Sinai Medical Center, Los Angeles, CA, USA) around his presentation discussing the clinical trial assessing the IBD&Me decision making tool.
The abstract ‘IMPACT OF AN INTERACTIVE IBD BIOLOGICS DECISION AID ON PATIENT OUTCOMES: RESULTS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL.’ (Abstract number: 982) was presented at Digestive Disease Week 2022, May 21-24, 2022.
- What are the challenges in selecting biologic therapies for patients with inflammatory bowel disease? (0:12)
- Could you give us a brief overview of the IBD&Me decision making tool? (0:54)
- Could you tell us a little about the clinical trial assessing this tool, and its findings? (2:31)
- What do you think were the reasons for the lack of difference between the study arms? (5:15)
- What should be the focus of future studies? (6:54)
Disclosures: Christopher Almario discloses consulting for Arena Pharmaceuticals and receiving grant/ research support from the Crohn’s & Colitis Foundation.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of DDW 2022.
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!